Health

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...

2026-05-31 08:09

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug con...

2026-05-31 08:00

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating...

2026-05-30 22:01 1570

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-genera...

2026-05-30 21:51 1459

Duke-NUS graduates biggest class yet, with new doctors drawn from business, engineering and the humanities

At his first graduation as Dean, Patrick Tan presides over a record class of 135 graduates, with Guest of Honour Mdm Rahayu Mahzam and keynote speaker Dr Robert Califf SINGAPORE, May 30, 2026 /PRNewswire/ -- From engineers and business graduates to literature and communications majors, Duke-NUS ...

2026-05-30 21:01 1661

XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies

BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second...

2026-05-29 22:10 3317

Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering

SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds ...

2026-05-29 22:00 3580

Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions

SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in ...

2026-05-29 21:08 2741

SKIA HEAD: AR Surgical Guidance Receives FDA 510(k) Clearance, Eyes U.S. Expansion with Structure Partnership

SEOUL, South Korea, May 29, 2026 /PRNewswire/ -- South Korea-based medtech innovator SKIA has announced that the U.S. Food and Drug Administration (FDA) has granted510(k) clearance for its augmented reality (AR) surgical guidance system,SKIA HEAD. This regulatory milestone clears the path for the...

2026-05-29 21:00 2207

Holmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral Health

Expansion anchored by two top neurological health systems, structured AD biomarker data, and validated outcomes measures across neurological disease areas. Whole-population ingestion shifts NeuroBlu from patient counts to research-grade signal. NEW YORK, May 29, 2026 /PRNewswire/ -- Holmusk toda...

2026-05-29 21:00 1504

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

* ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins * WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen...

2026-05-29 20:52 2232

CooperVision Names Muru Annamalai as President, Asia-Pacific

Experienced Global Healthcare Leader to Guide Growth Across the Region SINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1. He brings more than two decades of global leadership experience across the pharmaceutical and healthca...

2026-05-29 20:05 1945

SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund

* SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth Fund financing program * SK bioscience became the first Korean novel drug and vaccine deve...

2026-05-29 20:00 1838

RingConn Gen 3 Smart Ring Officially Launches: Expanding Long-Term Health Awareness in Everyday Life

World's Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 29, 2026 /PRNewswire/ -- RingConn officially launches the Gen 3 Smart Ring globally on May 29th, bringing vascular insights and continuous tracking into a refined ultra-lightweight wearable experience. Following pre-orde...

2026-05-29 19:00 1706

Vantage Foundation Brings Smiles and Support to Residents of Victory Old Folks Home in Malaysia

VANTAGE FOUNDATION × TOUCHING LIVES CLUB Community Outreach at Victory Old Folks Home, Puchong KUALA LUMPUR, Malaysia, May 29, 2026 /PRNewswire/ -- At Victory Old Folks Home in Puchong, Malaysia, a karaoke session turned into something more than entertainment. An elderly resident, initially quie...

2026-05-29 17:27 2702

Doctors at Omotesando Helene Clinic Publish New Study on Long-Term Safety Surveillance Following High-Dose Intravenous MSC Administration

Continuing clinical data analysis and academic publication in regenerative medicine and ATMP as the Tokyo clinical hub within Helene Bio Group TOKYO, May 29, 2026 /PRNewswire/ -- Medical Corporation HELENE Omotesando Helene Clinic, located in Minato-ku, Tokyo, is pleased to announce that a resea...

2026-05-29 13:50 2707

HMS Vision Inc. and Wenzhou Medical University Announce the Expansion of Their Simulation-Based Training Center During Vision China 2026

TIANJIN, China, May 29, 2026 /PRNewswire/ -- HMS Vision Inc. announced this week at Vision China 2026 the expansion of the HelpMeSee Simulation-based Eye Surgery Training Program at the Eye Hospital of Wenzhou Medical University (WMU). Since the collaboration began in 2018, the program has grown ...

2026-05-29 09:02 2645

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising ne...

2026-05-29 07:00 2802

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

* Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented. * The efficacy data highlight how the combination of elacestrant and capivasertib has the potential to address key resistance mechanisms for pa...

2026-05-29 00:02 3427

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

HOUSTON, May 28, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used ina recent study by Tencent AI for Life Sciences Lab publi...

2026-05-28 23:45 2972
12345 ... 874